A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO) ; volume:17 ; number:1 ; day:25 ; month:7 ; year:2017 ; pages:1-9 ; date:12.2017
BMC cancer ; 17, Heft 1 (25.7.2017), 1-9, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Decker, Thomas
- Contributor
-
Overkamp, Friedrich
Rösel, Siegfried
Nusch, Arnd
Göhler, Thomas
Indorf, Martin
Sahlmann, Jörg
Trarbach, Tanja
SpringerLink (Online service)
- DOI
-
10.1186/s12885-017-3492-1
- URN
-
urn:nbn:de:1111-201710067046
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Decker, Thomas
- Overkamp, Friedrich
- Rösel, Siegfried
- Nusch, Arnd
- Göhler, Thomas
- Indorf, Martin
- Sahlmann, Jörg
- Trarbach, Tanja
- SpringerLink (Online service)
Other Objects (12)
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pankreaskarzinom nab-Paclitaxel
History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future
Breast cancer nab-Paclitaxel
Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Pharmakokinetik der Taxane : (Paclitaxel und Docetaxel)
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pankreaskarzinom nab-Paclitaxel
History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future
Breast cancer nab-Paclitaxel
Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Pharmakokinetik der Taxane : (Paclitaxel und Docetaxel)
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pankreaskarzinom nab-Paclitaxel
History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future
Breast cancer nab-Paclitaxel
Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial